Efficacy data for VEGF inhibitors (also used for other STS) showed an ORR of 8.3% (95%CI: 0.2; 38.5), lower than reported data for chemotherapy and mTOR inhibitors, whereas the median PFS of 5.4 months was similar to the mTOR results. The gene discussed is MTOR; the disease is telomere syndrome.